Synced daily from ClinicalTrials.gov via AACT. Last sync: .
10 Pelareorep clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including Recurrent Plasma Cell Myeloma & Anal Cancer Metastatic) and 449 total planned enrollment. 1 Pelareorep clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07446322 (Apr 2030).
Where to Participate: All Pelareorep Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting Pelareoreptrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Terminated and withdrawn Pelareorep trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT04102618terminatedA Window-of-opportunity Study of Pelareorep in Early Breast Cancer
All Pelareorep trials (10)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
10 Pelareorep clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 4 are marked completed.
Are Pelareorep clinical trials recruiting in 2026?
Yes — 1 Pelareorep trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Pelareorep being studied for?
Pelareorep is being studied for Recurrent Plasma Cell Myeloma, Anal Cancer Metastatic, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Breast Cancer and 18 more. The trials are grouped by indication on this page.
What phase is Pelareorep in?
Pelareorep clinical trials span 4 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Pelareorep clinical trials?
The lead sponsor across the most Pelareorep trials is Oncolytics Biotech, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pelareorepas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.